Introduction
============

Measles, mumps, rubella and varicella are viral diseases associated with significant morbidity and mortality in children and sometimes linked with potentially life-threatening complications.[@R1]^-^[@R4] Effective vaccination strategies coupled with sustained high vaccination coverage can reduce the risk of transmission of such highly infectious viruses.[@R5] The success of a two-dose measles-mumps-rubella (MMR) vaccination strategy is evident in European countries where a significant reduction in disease morbidity and mortality has been noted.[@R6] On the other hand, although varicella vaccines are licensed in many countries, they are not always included in national immunization programs and as a result the vaccine uptake is low.[@R7] Nevertheless, evidence of the impact of universal varicella vaccine coverage (80%) has been observed in the United States and Uruguay.[@R6]^,^[@R8]^,^[@R9]

The Taiwan national immunization program incorporated two-dose MMR and one-dose varicella vaccinations as separate injections in 1992 and 2004, respectively.[@R10]^-^[@R12] Despite high coverage rates for the first-doses of MMR (96%) and varicella (97%) vaccinations, measles and varicella outbreaks and varicella breakthrough infections have occurred.[@R11]^-^[@R14] In Singapore, the introduction of two-dose MMR vaccination in 1999 resulted in a considerable decline in reported cases for all three diseases. While varicella vaccination has been available in Singapore since 1996, it is not included in the childhood vaccination schedule.[@R15]

A combined MMR-varicella vaccine (MMRV) may achieve the higher vaccination coverage rates needed to achieve the full benefits of varicella vaccination and facilitate the inclusion of varicella into national immunization programs.[@R16] Such a vaccine has the potential to provide broad protection against four diseases in a single injection and with minimum impact on vaccination program logistics.[@R16] A tetravalent MMRV vaccine was developed based on previous experience with MMR and varicella vaccines.[@R7] Previous studies have demonstrated that the MMRV vaccine is as immunogenic as separate MMR and varicella vaccines.[@R17]^-^[@R19] The MMRV vaccine is commercially available in Australia, Canada and several European countries as a two-dose schedule.[@R7]^,^[@R20]

Recently, production of GlaxoSmithKline's combined MMRV vaccine was switched to measles and rubella monovalent bulks derived from a newly established working seed virus stock (MMRV~new\ WS~) due to the depletion of the current working seed virus stock. The new working seed virus stock is one passage further than the current working seed virus stock. This study was undertaken to obtain clinical data on the immunogenicity and safety of MMRV~new\ WS~ by assessing its non-inferiority to MMRV when administered to healthy Taiwanese and Singaporean children.

Results
=======

Demographics
------------

Of 498 children enrolled in the study (332 in the MMRV~new\ WS~ group; 166 in the MMRV group), 475 were included in the according-to-protocol (ATP) cohort for immunogenicity (317 in the MMRV~new\ WS~ group; 158 in the MMRV group) ([Fig. 1](#F1){ref-type="fig"}). The 46 children (30 in the MMRV~new\ WS~ group; 16 in the MMRV group) who received commercially available MMRV vaccine as the second dose due to expiry of initial vaccine lots were included in the ATP cohort. The median age of children in the ATP cohort was 12 mo (range: 11--20 mo); 49.9% were female and the children were predominantly of East Asian (50.3%) and South-East Asian heritage (48.2%). Subject demographic characteristics did not differ between study groups.

![**Figure 1.** Study profile. MMRV~new\ WS~: measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock. MMRV, combined measles-mumps-rubella-varicella vaccine derived from current working seed virus stock; ATP, according-to-protocol.](hvi-9-1308-g1){#F1}

Immunogenicity
--------------

The proportion of children initially seropositive for measles, mumps, rubella and varicella was \< 3% in the MMRV~new\ WS~ and MMRV groups. Seroconversion rates for vaccine antigens ranged from 89.7% to 99.7% in the MMRV~new\ WS~ group and from 90.4% to 100% in the MMRV group, post-dose-1 ([Table 1](#T1){ref-type="table"}). In both groups, there was at least a 60 fold rise in the GMTs to varicella between doses 1 and 2. The primary non-inferiority objective was achieved for all vaccine antigens as the lower limit of the 95% CI for the group difference between MMRV~new\ WS~ and MMRV groups in terms of seroconversion rates 43 d post-dose-1 was greater than the pre-specified cut-off (-10%) ([Table 1](#T1){ref-type="table"}).

###### **Table 1.** Seroconversion rates and antibody GMTs in the MMRV~new\ WS~ and MMRV groups, 43 d after each dose (ATP cohort)

  Dose                                           MMRV~new\ WS~ group   MMRV group          Difference in SC rate (MMRV~new\ WS~ - MMRV)   P-value                                                                       
  ---------------------------------------------- --------------------- ------------------- ---------------------------------------------- --------- ------------------- ------------------------- --------------------- -----------
  Post-dose-1                                    314                   99.4 (97.7; 99.9)   3291.2 (3054.0; 3546.8)                        157       100 (97.7; 100)     3460.1 (3145.6; 3806.0)   -0.64 (-2.29; 1.76)   \< 0.0001
  Post-dose-2                                    308                   100 (98.8; 100)     4247.6 (3911.5; 4612.6)                        156       100 (97.7; 100)     4297.1 (3867.9; 4774.0)   \-                    \-
  **Anti-mumps (≥ 231 U/ml) -- ELISA**                                                                                                                                                                                  
  Post-dose-1                                    311                   89.7 (85.8; 92.9)   924.4 (821.9; 1039.7)                          157       90.4 (84.7; 94.6)   994.4 (851.7; 1161.0)     -0.74 (-6.14; 5.58)   0.0004
  Post-dose-2                                    307                   100 (98.8; 100)     3379.5 (3121.3; 3659.0)                        155       100 (97.6; 100)     3216.2 (2870.9; 3603.0)   \-                    \-
  **Anti-rubella (≥ 4 IU/ml) -- ELISA**                                                                                                                                                                                 
  Post-dose-1                                    314                   99.7 (98.2; 100)    71.7 (66.1; 77.9)                              157       100 (97.7; 100)     66.6 (59.3; 74.9)         -0.32 (-1.78; 2.08)   \< 0.0001
  Post-dose-2                                    308                   100 (98.8; 100)     125.7 (117.4; 134.5)                           156       100 (97.7; 100)     115.2 (104.2; 127.4)      \-                     
  **Anti-varicella (≥ 4 dilution^−1^) -- IFA**                                                                                                                                                                          
  Post-dose-1                                    291                   97.6 (95.1; 99.0)   104.8 (90.8; 120.9)                            141       92.9 (87.3; 96.5)   69.6 (53.6; 90.2)         4.69 (0.72; 10.34)    \< 0.0001
  Post-dose-2                                    286                   100 (98.7; 100)     6570.6 (5746.7; 7512.7)                        138       100 (97.4; 100)     5134.8 (4153.8; 6347.4)   \-                    \-
  **Anti-varicella (≥ 25 mIU/ml) -- ELISA**                                                                                                                                                                             
  Post-dose-1                                    310                   97.4 (95.0; 98.9)   138.0 (125.5; 151.6)                           156       92.3 (86.9; 96.0)   106.5 (90.5; 125.4)       \-                    \-
  Post-dose-2                                    304                   100 (98.8; 100)     2531.7 (2369.8; 2704.7)                        155       100 (97.6; 100)     2211.2 (2001.5; 2442.9)   \-                    \-

MMRV~new\ WS~, measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock; MMRV: measles-mumps-rubella-varicella vaccine derived from current working seed virus stock; ELISA, Enzyme-linked immunosorbent assay; IFA: immunofluorescence assay; N, number of children with available results; SC: seroconversion; GMT: geometric mean titers; 95% CI: Exact 95% confidence interval; P-value, one-sided asymptotic standardized test for H~0~: MMRV~new\ WS~ -- MMRV \< -10%; Note: 30 children in the MMRV~new\ WS~ group and 16 children in the MMRV group received commercially available MMRV vaccine as the second dose due to expiry of initial vaccine lots and were included in the ATP cohort.

Safety and reactogenicity
-------------------------

The overall incidence of symptoms (solicited and unsolicited) was 88.3% in the MMRV~new\ WS~ and 85.5% in the MMRV groups following dose-1; and 68.5% in the MMRV~new\ WS~ and 72.0% in the MMRV groups, following dose-2. Injection site redness was the most commonly reported solicited local and grade 3 symptom in both groups during the 4-d period after each dose ([Table 2](#T2){ref-type="table"}). Fever was the most commonly reported solicited general symptom in both groups during the 43-d period after each dose ([Table 3](#T3){ref-type="table"}). After dose-2, fever was reported for fewer children in both groups. A peak in the prevalence of fever between days 5 and 12 was observed post-dose-1 ([Fig. 2](#F2){ref-type="fig"}).

###### **Table 2.** Incidence of solicited local symptoms reported during the 4-d follow-up period in groups MMRV~new\ WS~ and MMRV (Total vaccinated cohort)

  ---------------------------------------------------------------------------------------------------------------------------------------
  Symptom    Dose          Type       MMRV~new\ WS~ group\               MMRV group\                                       
                                      (Dose-1 n = 330; Dose-2 n = 327)   (Dose-1 n = 166; Dose-2 n = 164)                  
  ---------- ------------- ---------- ---------------------------------- ---------------------------------- -------------- --------------
                           **%**      **(95% CI)**                       **%**                              **(95% CI)**   

  Pain       Post-dose-1   Any        18.8                               (14.7; 23.4)                       16.9           (11.5; 23.4)

             Grade 3       0.0        (0.0; 1.1)                         0.0                                (0.0; 2.2)     

             Post-dose-2   Any        14.1                               (10.5; 18.3)                       14.6           (9.6; 21.0)

                           Grade 3    0.0                                (0.0; 1.1)                         0.0            (0.0; 2.2)

  Redness    Post-dose-1   Any        27.9                               (23.1; 33.1)                       26.5           (20.0; 33.9)

             \> 20 mm      0.6        (0.1; 2.2)                         1.8                                (0.4; 5.2)     

             Post-dose-2   Any        24.2                               (19.6; 29.2)                       26.2           (19.7; 33.6)

                           \> 20 mm   1.2                                (0.3; 3.1)                         3.0            (1.0; 7.0)

  Swelling   Post-dose-1   Any        6.7                                (4.2; 9.9)                         6.6            (3.4; 11.5)

             \> 20 mm      0.0        (0.0; 1.1)                         0.0                                (0.0; 2.2)     

             Post-dose-2   Any        11.3                               (8.1; 15.3)                        15.2           (10.1; 21.7)

                           \> 20 mm   0.3                                (0.0; 1.7)                         0.0            (0.0; 2.2)
  ---------------------------------------------------------------------------------------------------------------------------------------

MMRV~new\ WS~, measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock; MMRV: measles-mumps-rubella-varicella vaccine derived from current working seed virus stock; N, number of children with at least one documented dose; %, Percentage of children reporting the symptom at least once; 95% CI, Exact 95% confidence interval

###### **Table 3.** Incidence of solicited general symptoms reported during the 43-d follow-up period in groups MMRV~new\ WS~ and MMRV (total vaccinated cohort)

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Symptom                  Dose                          MMRV~new\ WS~ group\          MMRV group\                                       
                                                         (Dose-1 n = 330;\             (Dose-1 n = 166;\                                 
                                                         Dose-2 n = 327)               Dose-2 n = 164)                                   
  ------------------------ ----------------------------- ----------------------------- ------------------- -------------- -------------- --------------
  **Fever (days 0--14)**   Post-dose-1                   Any                           61.8                (56.3; 67.1)   54.8           (46.9; 62.5)

                           Grade 3 (\> 39.5°C)           8.8                           (6.0; 12.4)         7.8            (4.2; 13.0)    

                           Related                       46.7                          (41.2; 52.2)        39.2           (31.7; 47.0)   

                           Medical advice                14.2                          (10.7; 18.5)        16.9           (11.5; 23.4)   

  Post-dose-2              Any                           19.0                          (14.9; 23.6)        25.6           (19.1; 33.0)   

                           Grade 3 (\> 39.5°C)           2.1                           (0.9; 4.4)          1.2            (0.1; 4.3)     

                           Related                       7.6                           (5.0; 11.1)         11.6           (7.1; 17.5)    

                           Medical advice                3.7                           (1.9; 6.3)          8.5            (4.7; 13.9)    

  **Fever (days 0--42)**   Post-dose-1                   Any                           70.0                (64.7; 74.9)   62.7           (54.8; 70.0)

                           Grade 3 (\> 39.5°C)           16.4                          (12.5; 20.8)        13.9           (9.0; 20.1)    

                           Related                       48.5                          (43.0; 54.0)        42.2           (34.6; 50.1)   

                           Medical advice                28.2                          (23.4; 33.4)        26.5           (20.0; 33.9)   

  Post-dose-2              Any                           35.2                          (30.0; 40.6)        37.8           (30.4; 45.7)   

                           Grade 3 (\> 39.5°C)           9.5                           (6.5; 13.2)         7.9            (4.3; 13.2)    

                           Related                       8.9                           (6.0; 12.5)         17.1           (11.7; 23.7)   

                           Medical advice                20.2                          (16.0; 24.9)        17.7           (12.2; 24.4)   

  **Rash**                 Post-dose-1                   Any (localized/generalized)   26.7                (22.0; 31.8)   25.3           (18.9; 32.6)

                           With fever                    17.9                          (13.9; 22.5)        15.1           (10.0; 21.4)   

                           Grade 3                       2.7                           (1.3; 5.1)          3.6            (1.3; 7.7)     

                           Related                       11.2                          (8.0; 15.1)         13.9           (9.0; 20.1)    

  Post-dose-2              Any (localized/generalized)   12.2                          (8.9; 16.3)         10.4           (6.2; 16.1)    

                           With fever                    4.9                           (2.8; 7.8)          5.5            (2.5; 10.2)    

                           Grade 3                       1.8                           (0.7; 4.0)          0.6            (0.0; 3.4)     

                           Related                       3.7                           (1.9; 6.3)          4.3            (1.7; 8.6)     
  -----------------------------------------------------------------------------------------------------------------------------------------------------

MMRV~new\ WS~, measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock; MMRV: measles-mumps-rubella-varicella vaccine derived from current working seed virus stock; N, number of children with at least one documented dose; %, Percentage of children reporting the symptom at least once; 95% CI, Exact 95% confidence interval.

![**Figure 2.** Prevalence of fever (any intensity) during the 43-d follow-up period after the first dose (Total vaccinated cohort). MMRV~new\ WS~: measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock. MMRV, combined measles-mumps-rubella-varicella vaccine derived from current working seed virus stock](hvi-9-1308-g2){#F2}

In the MMRV~new\ WS~ group, febrile convulsions occurring during the 43-d post-vaccination period were reported in two children (days 16 and 38 post-dose-1), accompanied by acute pharyngitis in the first child and viral infection in the second child. The second child experienced another febrile convulsion (day 18 post-dose-2) which was considered vaccine-related. In the MMRV group, a febrile convulsion accompanied by viral infection was reported for one child (day 39 post-dose-1). All cases post-dose-1 were considered unrelated to vaccination.

The incidence of unsolicited symptoms during the 43-d follow-up period were comparable between groups (49.7% and 44% in the MMRV~new\ WS~ and MMRV groups, respectively, post-dose-1 and 44% and 45.8%, respectively, post-dose-2). Upper respiratory tract infection was the most common unsolicited symptom post-dose-1 (15.1% and 13.3% in the MMRV~new\ WS~ and MMRV groups, respectively) and post-dose-2 (9% and 18.7% in the MMRV~new\ WS~ and MMRV groups, respectively). One or more SAEs were reported in 39 children (27 in the MMRV~new\ WS~ group; 12 in the MMRV group). Bronchiolitis, febrile convulsion and acute tonsillitis were the most commonly reported SAEs (each reported for four children in the MMRV~new\ WS~ group). In the MMRV group, bronchiolitis was the most commonly reported SAE occurring in four children. Two SAEs related to vaccination were reported in the MMRV~new\ WS~ group. One subject developed atypical Kawasaki disease (30 d post-dose-2). Another subject developed viral related encephalitis (24 d post-dose-2) accompanied by acute gastroenteritis norovirus infection and one seizure attack following hospitalization. The observed norovirus related seizure was considered unrelated to vaccination. All SAEs resolved without sequelae, except one (viral infection) in one MMRV~new\ WS~ recipient. No deaths occurred during the study.

Discussion
==========

The depletion of the current working seed virus stock justified the need for a new working seed virus stock. This study compared the immunogenicity and safety of a first dose of MMRV~new\ WS~ vaccine to that of the MMRV vaccine when administered to healthy Taiwanese and Singaporean children. The results demonstrated that immune responses to measles, mumps, rubella and varicella post-dose-1 of MMRV~new\ WS~ vaccine were non-inferior to that elicited by the MMRV vaccine. The primary non-inferiority criterion of ruling out a 10% difference in seroconversion rates post-dose-1 of MMRV~new\ WS~ compared with MMRV was achieved for all antigens.

The observed seroconversion rates and GMTs for all vaccine antigens indicated strong immune responses after each dose of the two vaccines, suggesting enhanced protection post-dose-2. Studies have reported similar results in the assessment of the MMRV vaccine in German children aged 11--21 mo[@R19] and Singaporean children aged 9 mo.[@R21] The strong increase in anti-varicella antibodies post-dose-2 in both vaccine groups is well-documented.[@R19]^,^[@R21] This is especially encouraging as it supports the two-dose schedule for varicella vaccine in providing better long-term protection against the disease in young children.

Both vaccines were well-tolerated and had clinically acceptable safety profiles, as reported previously.[@R17]^-^[@R19]^,^[@R21] The incidence of fever during the 15-d period after dose-1 indicated no difference between the MMRV~new\ WS~ and MMRV vaccines. The peak prevalence in fever between days 5 and 12 post-dose-1 is characteristic of measles-containing vaccines, typically described during the second week post-vaccination.[@R22] Moreover, the majority of cases reported for fever were low grade in intensity after each vaccine dose in both groups.

A vaccine-related febrile convulsion was reported in one child from the MMRV~new\ WS~ group, post-dose-2. Previous studies have indicated an increased risk of febrile convulsions in children administered with an initial dose of combined MMRV vaccine (Merck and Co., Inc., USA) specifically between 5--12 d[@R23] or 7--10 d[@R24] post-vaccination, as compared with co-administered MMR+V vaccines. A similar risk of febrile convulsions can be expected with this study's MMRV vaccine since a recent study has reported comparable fever profiles between GlaxoSmithKline's and Merck's combined MMRV vaccines.[@R25] Higher rates of fever have also been reported with the study MMRV vaccine compared with co-administration of MMR+V.[@R17]^-^[@R19] Given this concern, the American Academy of Pediatrics recommends the use of either single dose co-administration of MMR+V or combined MMRV vaccine in children 12--47 mo of age.[@R24] In cases where MMRV usage is being considered, the benefits and risks associated with the vaccine need to be conveyed to parents/guardians.[@R26] Although the incidence of febrile convulsions is low in the present study, it is important to note that this study excluded children with a history of neurologic disease and seizures. Children with a history of febrile seizures are at high risk for recurrent febrile seizures.[@R27] Inclusion of such children may have resulted in a higher number of reported febrile seizures in this study.

One vaccine-related SAE occurred: norovirus infection coupled with seizure. However, norovirus gastroenteritis has previously been reported to be a significant cause of diarrhea-associated benign infant seizures.[@R28]

Our study results demonstrated non-inferiority of the immune responses elicited by the MMRV~new\ WS~ vaccine to that elicited by the MMRV vaccine. The MMRV~new\ WS~ vaccine was found to be generally well tolerated in Taiwanese and Singaporean children.

Materials and Methods
=====================

Study design and children
-------------------------

This phase II, randomized, double-blind study (NCT00892775) was conducted at multiple centers in Singapore and Taiwan between June 2009 and December 2010. Healthy children aged 11--22 mo were randomized (2:1) to receive two doses of either the MMRV vaccine derived from new working seed viruses (MMRV~new\ WS~ group) or the MMRV vaccine derived from current working seed viruses (MMRV group). Due to expiry of the initial vaccine lots, 46 children (30 in the MMRV~new\ WS~ group; 16 in the MMRV group) received commercially available MMRV vaccine as a second dose.

Children were excluded from participation if they had received any investigational drug/vaccine 30 d before the study vaccine or immunosuppressive medication/immunoglobulins/blood products six months before the study. A history of allergy likely to be aggravated by any of the vaccine constituents, neurological disease or seizures, chronic illness or family history of immunodeficiency or symptoms of acute illness at the time of enrolment were reasons for exclusion. Vaccination was postponed for children with a rectal temperature ≥ 38.0°C or an axillary temperature ≥ 37.5°C. Finally, children were excluded if they lived in a household with newborn infants, pregnant women with a negative history of chickenpox or immunodeficient people.

The study was conducted according to Good Clinical Practice, the Declaration of Helsinki and applicable rules and regulations of Taiwan and Singapore. Each participating center's Independent Ethics Committee reviewed and approved all study-related documents. Parents/guardians provided written informed consent before executing any study-related procedures.

Study vaccines
--------------

The study vaccines, MMRV~new\ WS~ and MMRV, were manufactured by GlaxoSmithKline, Belgium ([Table 4](#T4){ref-type="table"}). The vaccines were supplied in monodose vials, each containing a lyophilized pellet which was reconstituted with the diluent (provided in a pre-filled syringe) as a 0.5 ml dose before subcutaneous injection in the upper arm (deltoid region).

###### **Table 4.** Composition of study vaccines

  Vaccine         Minimum viral titer after reconstitution                           
  --------------- ------------------------------------------ ----------- ----------- -----------
  MMRV~new\ WS~   ≥ 10^3.0^                                  ≥ 10^4.4^   ≥ 10^3.0^   ≥ 10^3.3^
  MMRV            ≥ 10^3.0^                                  ≥ 10^3.7^   ≥ 10^3.0^   ≥ 10^3.3^

CCID~50~, median cell culture infective dose; Pfu, plaque-forming units

Immunogenicity assessment
-------------------------

Blood samples were collected at pre-vaccination and 43 d after each dose. Antibody titers were measured using commercial enzyme-linked immunosorbent assays (ELISA) -- (*Enzygnost™*, Dade Behring, Marburg, Germany) with cut-off values of 150 mIU/mL, 231 U/mL and 4 IU/mL for measles, mumps and rubella, respectively. For varicella, antibody titers were measured using an immunoflorescence assay (IFA) -- (*Virgo™*, Hemagen Diagnostics, Columbia, MD, USA) (cut-off value of 4 dilution^−1^). The primary endpoint was based on immune responses following dose-1 of both vaccines. Additionally, antibody titers against varicella using ELISA (cut-off = 25 mIU/mL) were measured.

Safety/Reactogenicity assessment
--------------------------------

Parents/guardians used diary cards to record the occurrence of solicited local symptoms (pain, redness and swelling) at the injection site for 4 d after each dose and solicited general symptoms \[fever (axillary temperature ≥ 37.5°C/rectal temperature ≥ 38.0°C), rash/exanthem, parotid/salivary gland swelling and any suspected signs of meningism, including febrile convulsions\] for 43 d after each dose. Body temperature was measured daily via the rectal/axillary route for the first 15 d after each vaccination. Between days 15 and 43, the presence of fever was assessed using a temperature-sensitive pad, and if fever was suspected, an accurate measurement of temperature was performed with a thermometer. Unsolicited symptoms were recorded for 43 d after each dose and serious adverse events (SAEs) were recorded throughout the study.

Intensity of symptoms was graded on a scale of 0--3. Grade 3 solicited symptoms were defined as: pain: when limb was moved or a spontaneously painful limb; redness and swelling: injection site surface diameter \> 20 mm; fever: axillary temperature \> 39°C or rectal temperature \> 39.5°C; rash: \> 150 lesions. Unsolicited symptoms (including SAEs) were defined as grade 3 when preventing normal daily activity.

Statistical analyses
--------------------

All statistical analyses were performed using Statistical Analysis Software (SAS) version 9.2, and 95% confidence intervals (CI) were calculated using Proc StatXact 8.1. The sample size was estimated taking into consideration the primary non-inferiority objective. Non-inferiority was achieved if the lower limit of the two-sided standardized asymptotic 95% CI for the difference in seroconversion rates between the two groups (MMRV~new\ WS~ minus MMRV) was above -10% for each vaccine antigen, post-dose-1. A sample size of 498 children (332 in the MMRV~new\ WS~ group; 166 in the MMRV group), considering approximately a 15% drop-out rate was planned. To meet the primary objective, 420 evaluable children (280 in the MMRV~new\ WS~ group; 140 in the MMRV group) were adequate to achieve a power of at least 93.4%. A randomized (2:1) blocking scheme ensured that the balance between treatments was maintained by providing a unique treatment number that identified the vaccine dose to be administered to the children.

The immunogenicity analysis was performed on the ATP cohort, which included all children for whom pre- and post-dose-1 vaccination serology results were available, who were seronegative for at least one vaccine antigen before vaccination and who complied with study procedures. Seroconversion rates and geometric mean titers (GMTs) were calculated with exact 95% CIs for antibodies against each vaccine antigen after each dose. Seroconversion was defined as the appearance of antibodies (i.e., antibody concentration/titer ≥ cut-off value) in the serum of children who were seronegative before vaccination. The 95% CIs for the GMTs were obtained by exponential transformation of the 95% CI for the mean of log-transformed titer.

The safety analysis was performed on the total vaccinated cohort which included all vaccinated children. Solicited and unsolicited symptoms reported within their respective post-vaccination periods were tabulated with exact 95% CI. All SAEs reported throughout the study were described.

The authors thank all the investigators involved in this clinical trial conducted in Taiwan and Singapore. The authors also thank the study nurses and other staff members involved and the parents and children who participated in the study. The authors acknowledge Christopher da Costa (ex-employee of GSK Vaccines) for his contributions on the study design; Bruce Innis for his critical contributions to the overall study design and interpretation of the data; Pierre Cambron for serology testing; Ann Delforge for study coordination; Valerie Balosso for clinical data coordination; Ashmita Ravishankar for manuscript writing and K Manjula for publication management (all employees of GSK Vaccines).

*Virgo* is a registered trademark of Hemagen Diagnostics, Columbia, MD, USA. *Enzygnost* is a registered trademark of Dade Behring, Marburg, Germany.

Previously published online: [www.landesbioscience.com/journals/vaccines/article/24035](http://www.landesbioscience.com/journals/vaccines/article/24035/)

ATP
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CCID~50~
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MMR

:   measles-mumps-rubella vaccine

MMRV

:   measles-mumps-rubella-varicella vaccine

MMRV~new\ WS~

:   measles-mumps-rubella-varicella vaccine manufactured with measles and rubella monovalent bulks derived from a newly established working seed virus

SAE

:   serious adverse event
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